Evidence map›Paper›PMID 26529257›Full record

ArticleThe Journal of clinical investigation2015

Myo9b is a key player in SLIT/ROBO-mediated lung tumor suppression.

Ruirui Kong, Fengshuang Yi, Pushuai Wen, Jianghong Liu, Xiaoping Chen, Jinqi Ren, Xiaofei Li, Yulong Shang, Yongzhan Nie, Kaichun Wu and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of clinical investigation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 59 papers.

0numbers the graph read from it
0cells of the map it votes in
59citing papers in PubMed
2.8field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

59 citing papers in PubMed, 84 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Myosin IXB protects immune cells from virus infection.The Journal of general virology · 2025
    Article
  7. First Iranian Family with a Novel Missense Variant inArchives of Iranian medicine · 2025
    Article
  8. Article
  9. Article
  10. Integrative Computational Framework,bioRxiv : the preprint server for biology · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Ruirui Kong
Fengshuang Yi
Pushuai Wen
Jianghong Liu
Xiaoping Chen
Jinqi Ren
Xiaofei Li
Yulong Shang
Yongzhan Nie
Kaichun Wu
Daiming Fan
Li Zhu
Wei Feng
Jane Y Wu
State Key Laboratory of Brain and Cognitive ScienceInstitute of Biophysics · CNChinese Academy of Sciences · CNTang Du Hospital · CN

Funding

The role of deubiquitinating enzyme USP33 in Slit-Robo signaling in lung cancerR01CA175360 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI WU, JANE Y · 2014 to 2018
$2.2M
Mechanisms regulating tau alternative pre-mRNA splicingR01AG033004 · NIA · NORTHWESTERN UNIVERSITY AT CHICAGO · PI WU, JANE Y · 2011 to 2015
$1.5M
NCI NIH HHS R01 CA175360NCI NIH HHS R01CA175360NIA NIH HHS R01 AG033004NIA NIH HHS R01AG033004
6 · The paper itself

Abstract

Emerging evidence indicates that the neuronal guidance molecule SLIT plays a role in tumor suppression, as SLIT-encoding genes are inactivated in several types of cancer, including lung cancer; however, it is not clear how SLIT functions in lung cancer. Here, our data show that SLIT inhibits cancer cell migration by activating RhoA and that myosin 9b (Myo9b) is a ROBO-interacting protein that suppresses RhoA activity in lung cancer cells. Structural analyses revealed that the RhoGAP domain of Myo9b contains a unique patch that specifically recognizes RhoA. We also determined that the ROBO intracellular domain interacts with the Myo9b RhoGAP domain and inhibits its activity; therefore, SLIT-dependent activation of RhoA is mediated by ROBO inhibition of Myo9b. In a murine model, compared with control lung cancer cells, SLIT-expressing cells had a decreased capacity for tumor formation and lung metastasis. Evaluation of human lung cancer and adjacent nontumor tissues revealed that Myo9b is upregulated in the cancer tissue. Moreover, elevated Myo9b expression was associated with lung cancer progression and poor prognosis. Together, our data identify Myo9b as a key player in lung cancer and as a ROBO-interacting protein in what is, to the best of our knowledge, a newly defined SLIT/ROBO/Myo9b/RhoA signaling pathway that restricts lung cancer progression and metastasis. Additionally, our work suggests that targeting the SLIT/ROBO/Myo9b/RhoA pathway has potential as a diagnostic and therapeutic strategy for lung cancer.

Indexed as

Signal TransductionAnimalsCell Line, TumorFemaleGlycoproteinsHumansLung NeoplasmsMiceMice, Inbred BALB CMice, NudeMyosinsNerve Tissue ProteinsReceptors, ImmunologicrhoA GTP-Binding ProteinRoundabout ProteinsTumor Suppressor ProteinsGlycoproteinsmyosin IXBMyosinsNerve Tissue ProteinsReceptors, ImmunologicrhoA GTP-Binding ProteinRHOA protein, humanRoundabout Proteinsslit protein, vertebrateTumor Suppressor Proteins

Identifiers

PMID26529257
PMCPMC4665778
OpenAlexW1955938832

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.